Curtana Pharmaceuticals was founded on an uncompromising commitment: the current standard of care for brain cancer is fundamentally inadequate. Traditional therapies primarily target the rapidly dividing cells of the tumor bulk, leaving behind a highly resilient subpopulation of cancer stem cells (CSCs) that inevitably drive disease recurrence.
We are a team of veteran drug developers, world-class neuro-oncologists, and dedicated researchers united by the urgent need to change this paradigm. Our distinct approach centers on targeting OLIG2, a master transcription factor universally expressed in diffuse gliomas that serves as the central engine for CSC survival, proliferation, and tumor-driven immune evasion.
With our lead investigational asset, CT-179, we have successfully developed a first-in-class, highly brain-penetrant small molecule designed to physically disrupt OLIG2 dimerization, effectively neutralizing its ability to fuel tumor growth and hide the tumor from the immune system.
By aggressively targeting the cellular origin of treatment resistance across the most devastating adult and pediatric central nervous system malignancies – including Glioblastoma (GBM), Low Grade Glioma (LGG), Diffuse Midline Glioma (DMG), and Recurrent Medulloblastoma – we are advancing a new era of precision neuro-oncology. At Curtana, we refuse to accept recurrence as an inevitability; we are dismantling brain cancer at its foundation.
